The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Last updated: July 21, 2020
Sponsor: Peking University People's Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Platelet Disorders

Immune (Idiopathic) Thrombocytopenic Purpura (Itp)

Thrombosis

Treatment

N/A

Clinical Study ID

NCT04481282
ITP-PKU010
  • Ages > 18
  • All Genders

Study Summary

Single-arm, open-label, single center study to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid resistant/relapsed ITP.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ITP confirmed by excluding other supervened causes of thrombocytopenia;

  • Platelet count of less than 30×10^9/L at enrollment;

  • Patients who did not achieve a sustained response to treatment with full dosecorticosteroids for a minimum duration of 4 weeks or who relapsed duringsteroid-tapering or after its discontinuation;

  • Subject has signed and dated written informed consent.

  • Fertile patients must use effective contraception during treatment and observationalperiod

  • Negative pregnancy test.

Exclusion

Exclusion Criteria:

  • Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pyloriinfection or patients with systemic lupus erythematosus)

  • congestive heart failure

  • severe arrhythmia

  • nursing or pregnant women

  • aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of thenormal threshold criteria

  • creatinine or serum bilirubin levels each 1•5 times or more than the normal range

  • active or previous malignancy

  • Unable to do blood routine test for the sake of time, distance, economic issues orother reasons.

  • diagnosis with any of the following diseases: chronic hypertension, hyperthyroidism,diabetes, or seizure disorder.

Study Design

Total Participants: 40
Study Start date:
July 08, 2020
Estimated Completion Date:
July 31, 2021

Study Description

Immune thrombocytopenia (ITP) is a severe bleeding disorder. Approximately 2/3 of patients achieve remission from first-line therapies. However, the underlying mechanism of corticosteroid-resistant or relapsed ITP is not well understood; thus, treatment remains a great challenge. β2-AR agonist terbutaline modulates T cell differentiation and effector cell function.

A single center prospective study was performed in non-splenectomized ITP patients who were either resistant to a standard dose of corticosteroids or had relapsed. Patients were assigned to terbutaline plus danazol group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study, in order to assess the efficacy and safety of terbutaline plus danazol in patients with corticosteroid-resistant/relapsed ITP.

Connect with a study center

  • Peking University Insititute of Hematology, Peking University People's Hospital

    Beijing, Beijing 100010
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.